“Sarcopenia Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Sarcopenia Market.
The Sarcopenia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Sarcopenia Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Sarcopenia and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Sarcopenia market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Sarcopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Molecule Type
Products have been categorized under various Molecule types, such as
Oligonucleotide
Peptide
Small molecule
Learn How the Ongoing Clinical & Commercial Activities will Affect the Sarcopenia Therapeutic Segment @
https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight
Sarcopenia Therapeutics Landscape
There are approx. 12+ key companies developing therapies for Sarcopenia. Currently, Biophytis is leading the therapeutics market with its Sarcopenia drug candidates in the most advanced stage of clinical development.
Latest Key Update in the Sarcopenia Therapeutics Market
On April 12, 2023, MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”) announced a dosing update on its fully-funded Phase 2 clinical trial of lead drug candidate MYMD-1®, an orally available next-generation TNF-alpha inhibitor, as a therapy for chronic inflammation associated with sarcopenia and frailty (NCT05283486).
The Leading Players in the Sarcopenia Therapeutics Market Include:
Actimed Therapeutics
Biophytis
Dystrogen Therapeutics
Eli Lily
Faraday Pharmaceuticals
Immunoforge
Lipocine Inc.
MyMD Pharmaceuticals
NMD Pharma
Novartis
Oncocross Therapeutics
OPKO health
Pephexia Therapeutics
Regeneron Pharmaceuticals
Rejuvenate Biomed
Rubedo Life Sciences
Sanofi
And Many Others
Sarcopenia Emerging and Marketed Drugs Covered in the Report Include:
Sarconeos (BIO101): Biophytis
MYMD-1: MyMD Pharmaceuticals
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Sarcopenia Current Treatment Patterns
4. Sarcopenia – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Sarcopenia Late Stage Products (Phase-III)
7. Sarcopenia Mid-Stage Products (Phase-II)
8. Sarcopenia Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Sarcopenia Discontinued Products
13. Sarcopenia Product Profiles
14. Key Companies in the Sarcopenia Market
15. Key Products in the Sarcopenia Therapeutics Segment
16. Dormant and Discontinued Products
17. Sarcopenia Unmet Needs
18. Sarcopenia Future Perspectives
19. Sarcopenia Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services and Solutions
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
